No profile data available.
Lenz Therapeutics, Inc. (LENZ) is a healthcare company in the eye treatment pharmaceuticals industry, based in Solana Beach, United States, with about 152 full-time employees.
In Q3 2025 (the quarter ended September 30, 2025) revenue was $12.50 million. Its market capitalization was $114.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc.
$114.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Lineage Cell Therapeutics, Inc. (LCTX), Opus Genetics, Inc. (IRD), Outlook Therapeutics, Inc. (OTLK), Okyo Pharma Limited (OKYO).